Skip to main content
Clinical Trial Compass
Back to search
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-ce… (NCT03223610) | Clinical Trial Compass